Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -168,385 | -134,842 | -103,691 | -63,169 | -135,956 |
| Depreciation Amortization | -11,405 | -8,796 | -6,304 | -3,384 | -15,030 |
| Accounts payable and accrued liabilities | 206 | 1,533 | 1,218 | 16,885 | 1,701 |
| Other Working Capital | -7,476 | 1,066 | 2,622 | 14,102 | 16,163 |
| Other Operating Activity | 51,561 | 35,937 | 24,088 | -4,299 | 47,727 |
| Operating Cash Flow | $-135,499 | $-105,102 | $-82,067 | $-39,865 | $-85,395 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 56,105 | 59,475 | 355,948 | 56,802 | 40,303 |
| PPE Investments | N/A | N/A | -174,460 | N/A | N/A |
| Investing Cash Flow | $56,105 | $59,475 | $181,488 | $56,802 | $40,303 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 267 | 267 | 150 | 150 | 257 |
| Financing Cash Flow | $267 | $267 | $150 | $150 | $257 |
| Beginning Cash Position | 143,823 | 143,823 | 143,823 | 143,823 | 188,658 |
| End Cash Position | 64,696 | 98,463 | 243,394 | 160,910 | 143,823 |
| Net Cash Flow | $-79,127 | $-45,360 | $99,571 | $17,087 | $-44,835 |
| Free Cash Flow | |||||
| Operating Cash Flow | -135,499 | -105,102 | -82,067 | -39,865 | -85,395 |
| Capital Expenditure | N/A | N/A | -174,460 | N/A | N/A |
| Free Cash Flow | -135,499 | -105,102 | -256,527 | -39,865 | -85,395 |